Paying users zone. Data is covered by .

  • Get to Bristol-Myers Squibb Co. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

 

$15.99


Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Bristol-Myers Squibb Co., EBITDA calculation

USD $ in millions

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net earnings attributable to BMS
Add: Net income attributable to noncontrolling interest
Add: Income tax expense
Earnings before tax (EBT)
Add: Interest expense
Earnings before interest and tax (EBIT)
Add: Depreciation and amortization, net
Earnings before interest, tax, depreciation and amortization (EBITDA)
Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. Bristol-Myers Squibb Co.'s EBITDA increased from 2015 to 2016 but then slightly declined from 2016 to 2017.

Top


Enterprise Value to EBITDA Ratio, Current

Bristol-Myers Squibb Co., current EV/EBITDA calculation, comparison to benchmarks

 
Selected Financial Data (USD $ in millions)
Enterprise value (EV)
Earnings before interest, tax, depreciation and amortization (EBITDA)
Ratio
EV/EBITDA
Benchmarks
EV/EBITDA, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
EV/EBITDA, Sector
Pharmaceuticals & Biotechnology
EV/EBITDA, Industry
Health Care

If company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.

Otherwise, if company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.

Top


Enterprise Value to EBITDA Ratio, Historical

Bristol-Myers Squibb Co., historical EV/EBITDA calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Enterprise value (EV)1
Earnings before interest, tax, depreciation and amortization (EBITDA)2
Ratio
EV/EBITDA3
Benchmarks
EV/EBITDA, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
EV/EBITDA, Sector
Pharmaceuticals & Biotechnology
EV/EBITDA, Industry
Health Care

2017 Calculations

3 EV/EBITDA = EV ÷ EBITDA
= ÷ =

Ratio Description The company
EV/EBITDA EV/EBITDA is a valuation indicator for the overall company rather than common stock. Bristol-Myers Squibb Co.'s EV/EBITDA ratio declined from 2015 to 2016 but then slightly increased from 2016 to 2017.

Top